LRRK2 and Parkinson disease: Studies with more diverse samples representing individuals from a range of genetic ancestries and with larger sample sizes of individuals with both G2019S and non-G2019S pathogenic variants in LRRK2 gene variants are needed to clarify the effect of genetic modifiers in general, and LRRK2 genotype in particular, on CSF asyn SAA and other clinical and biomarker characteristics among individuals diagnosed with Parkinson’s disease.